Information Manufacturing Patients Relationship 
CDOCS
AUGUST 11, 2021
<p><span style="font-size:14px;">I have a love/hate relationship with the Copy and Mirror function in the software. </span></p> <p><span style="font-size:14px;">This patient presented with a chief complaint of his poorly matching crown on tooth #9. .</span></p>
FDA Law
MAY 8, 2023
The discussion paper described a PCCP as including (1) the types of anticipated modifications (SaMD Pre-Specifications or SPS) based on the retraining and model update strategy and (2) the associated methodology (Algorithm Change Protocol or ACP) being used to implement those changes in a controlled manner to manage patient risks.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
FDA Law
DECEMBER 12, 2022
Shapiro — Last summer, FDA published a draft guidance, Laser-Assisted In Situ Keratomileusis (LASIK) Lasers – Patient Labeling Recommendations (July 29, 2022) setting forth a proposal for new recommended patient‑directed labeling. The approved devices already have patient‑directed labeling that FDA has approved. By Jeffrey K.
GeriPal
JUNE 20, 2024
Widera and Smith have no relationships to disclose. Guests George Kuchel & Alison Huang have no relationships to disclose. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. I don’t see those perspectives as incompatible.
Physician's Practice
JUNE 9, 2025
a health care attorney and practice group manager with Roetzel & Andress, joins the show to break down the hidden legal risks of prescribing GLP-1 medications that physicians need to know about, from ensuring informed consent to navigating long-term safety data. 68: Hidden risks of prescribing GLP-1 drugs with Ericka L. Adler, J.D.,
FDA Law
SEPTEMBER 6, 2022
Below we outline the Draft Guidance and highlight the new information in the 2022 Draft Guidance. For this last question, FDA explains that it anticipates the sponsor would charge the patient directly or would charge a payor if reimbursement were available, but clearly states that FDA has no authority in this arena.
FDA Law
MAY 7, 2025
Regulatory Framework The AKS makes it a criminal felony to knowingly and willfully offer or pay any remuneration, directly or indirectly, to induce a person to order or refer patients for medical care that is reimbursable under a federal healthcare program (e.g., Medicare or Medicaid).
Expert insights. Personalized for you.
52 
Let's personalize your content